Kestra Medical Q1 Net Loss Widens Despite 60% Revenue Growth; Raises FY27 Outlook; Shares Fall

Kestra Medical Technologies reported a wider net loss in the first quarter ended July 31, 2026, even as revenue surged 60%. Net loss rose to $44.09 million, or $0.75 per share, from $25.83 million, or $0.50 per share a year earlier. Revenue jumped to $30.97 million from $19.37 million, driven by wearable cardioverter defibrillator (WCD) market expansion, competitive share gains and new sales territories. The operating loss widened to $37.66 million from $28.88 million. For full-year 2027, the company raised revenue guidance to $141 million from $137 million, forecasting 48% growth versus $95.1 million in 2026. Cash and investments totaled $244.7 million.